Literature DB >> 11111119

Premarital screening of beta-thalassemia trait in the province of Denizli, Turkey.

A Keskin1, T Türk, A Polat, H Koyuncu, B Saracoglu.   

Abstract

A premarital screening program aiming at reducing the incidence of thalassemia major was started under the auspices of the Regional Health Administration in 1995 in the city of Denizli in the Aegean region of Turkey. In this report we assessed the 4-year results of the screening program. All couples who applied for marriage procedures were screened for beta-thalassemia trait by automatic red cell indices and Hb A(2) determination. The couples at risk were counseled and offered prenatal diagnosis and termination of pregnancy in case of an affected fetus. From October 1995 to August 1999, a total of 19,804 subjects (9,902 couples) were recruited for this study. The prevalence of beta-thalassemia trait with increased Hb A(2) was found to be 2.6% (514/19,804). In addition to the thalassemia trait, 22 patients (0.11%) had sickle trait. In 15 of the 9,902 couples, both partners were found to be carriers of the beta-thalassemia trait. After genetic counseling, 2 of the 15 planned carrier marriages were canceled. Seven couples declared that they do not want to have a child at present. Prenatal diagnosis was sought by 6 couples. One fetus was found to be normal, 4 had thalassemia minor and 1 had thalassemia major; this pregnancy was terminated by elective abortion. This study indicated that premarital screening is a very useful tool for detecting carrier couples and an effective way of controlling thalassemia major. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11111119     DOI: 10.1159/000041066

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  9 in total

Review 1.  Getting married in China: pass the medical first.

Authors:  Therese Hesketh
Journal:  BMJ       Date:  2003-02-01

Review 2.  Carrier screening for beta-thalassaemia: a review of international practice.

Authors:  Nicole E Cousens; Clara L Gaff; Sylvia A Metcalfe; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

3.  Frequency of β-thalassemia trait and other hemoglobinopathies in northern and western India.

Authors:  Nishi Madan; Satendra Sharma; S K Sood; Roshan Colah; Late H M Bhatia
Journal:  Indian J Hum Genet       Date:  2010-01

4.  Ethical, social, and cultural issues related to clinical genetic testing and counseling in low- and middle-income countries: a systematic review.

Authors:  Adrina Zhong; Benedict Darren; Bethina Loiseau; Li Qun Betty He; Trillium Chang; Jessica Hill; Helen Dimaras
Journal:  Genet Med       Date:  2018-08-03       Impact factor: 8.822

5.  Preconceptional genetic carrier testing and the commercial offer directly-to-consumers.

Authors:  Pascal Borry; Lidewij Henneman; Phillis Lakeman; Leo P ten Kate; Martina C Cornel; Heidi C Howard
Journal:  Hum Reprod       Date:  2011-02-28       Impact factor: 6.918

6.  Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and β-thalassemia in Saudi Arabia.

Authors:  Ziad Ahmed Memish; Mohammad Y Saeedi
Journal:  Ann Saudi Med       Date:  2011 May-Jun       Impact factor: 1.526

7.  Unique pattern of mutations in β-thalassemia patients in Western Uttar Pradesh.

Authors:  Ajay F Christopher; Anita Kumari; Sunali Chaudhary; Sandhya Hora; Ziledar Ali; Satish C Agrawal
Journal:  Indian J Hum Genet       Date:  2013-04

8.  Evaluation and cost analysis of national health policy of thalassaemia screening in west-azerbaijan province of iran.

Authors:  Elham Ahmadnezhad; Nariman Sepehrvand; Farshid Fayyaz Jahani; Sanaz Hatami; Catauon Kargar; Majid Mirmohammadkhani; Shahrzad Bazargan-Hejazi
Journal:  Int J Prev Med       Date:  2012-10

9.  Premarital Screening of Beta Thalassemia Minor in north-east of Iran.

Authors:  H Hashemizadeh; R Noori
Journal:  Iran J Ped Hematol Oncol       Date:  2013-01-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.